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The impact of cancer on diabetes
outcomes
Anne Beiter Arreskov1* , Maria Å. Olsen1, Sandra Sinius Pouplier1, Volkert Siersma1, Christen L. Andersen1,
Søren Friis2 and Niels de Fine Olivarius1
Abstract
Background: Survival from many cancer types is steadily increasing, and as a result, a growing number of cancer
patients will live with other chronic diseases, of which diabetes is one of the most prevalent. This study aims to
describe the impact of cancer on health outcomes in patients with type 2 diabetes and to compare the
effectiveness of a multifactorial intervention in diabetes patients with and without cancer.
Methods: The randomized controlled trial Diabetes Care in General Practice (DCGP) included 1381 patients newly
diagnosed with type 2 diabetes. Patients were randomized to either six years of structured personal diabetes care
or routine care. In a post hoc analysis, we followed patients for 19 years in Danish national registries for the
occurrence of diabetes-related outcomes. We used Cox regression models to estimate hazard ratios for outcomes.
Results: At diagnosis 48 patients had cancer, and 243 patients were diagnosed with cancer during follow up.
Patients with diabetes and cancer had excess all-cause mortality (HR 3.33; 95%CI 2.72–4.06), as well as an increased
incidence of myocardial infarction (HR 1.76; 95%CI 1.29–2.39) and any diabetes-related outcome (HR 1.36; 95%CI
1.07–1.71). The intervention reduced the risk of both these endpoints in patients without cancer. Furthermore, there
was no statistically significant difference in the effectiveness of the intervention among patients with and without
cancer.
Conclusions: Diabetes patients with cancer had an increased risk of myocardial infarction and any diabetes-related
outcome. The observed positive effect of structured personal diabetes care on clinical outcomes did not differ
between patients with and without cancer. Attention to and prevention of diabetes complications in patients with
both type 2 diabetes and cancer is warranted.
Trial registration: ClinicalTrials.gov NCT01074762 (February 24, 2010).
Keywords: Type 2 diabetes, Diabetes care, Cancer, Diabetes complication, All-cause mortality, Primary care,
Randomized controlled trial
Background
Survival from many cancer types is steadily increasing
[1]. As a result, a growing number of patients with can-
cer will live with other chronic diseases, of which dia-
betes is one of the most prevalent [2]. Besides giving rise
to diabetes-related complications and death [3], type 2
diabetes in itself represents a risk factor for developing
several types of cancer, e.g., pancreatic, liver, colorectal,
breast, urinary tract, and female reproductive cancers
[4]. Therefore, the number of cancer patients with dia-
betes will increase disproportionately [5].
Treating patients with both cancer and diabetes to di-
minish symptoms and improve quality of life is import-
ant. However, the management of diabetes in cancer
patients is often complicated [6, 7]. For instance, the
diagnosis and treatment of cancer may distract both pa-
tients, and health care providers form the appropriate
management of diabetes. E.g., older studies show that
regular chronic care of, e.g., DM. COPD and CVD is less
common in patients who have completed primary cancer
treatment compared to patients with no cancer [8–11],
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implying that for cancer patients with diabetes, both
mortality and incidence of complications are increased
compared to cancer patients without diabetes [12, 13].
Increased focus on improving the diabetes manage-
ment of patients with both diabetes and cancer could
lower the incidence of diabetes-related complications
and mortality among these patients. However, while
many studies describe how diabetes affects the incidence
and mortality of cancer [14, 15], studies on the impact
of cancer on diabetes-related outcomes are rare [8, 9].
Therefore, we studied the influence of a cancer
diagnosis on the outcomes of diabetes management in
the population-based cohort from the Diabetes Care
in General Practice (DCGP) trial [16]. In this trial pa-
tients with newly diagnosed type 2 diabetes were ran-
domized to receive either structured personal diabetes
care or routine care. The intervention period lasted 6
years and patients were managed by their general
practitioners (GPs). Results from this study showed
that the intervention had a long-term effect on myo-
cardial infarction (MI) and on the aggregate endpoint
any diabetes-related outcomes.
The present analysis is a 19-year follow-up and obser-
vational post hoc analysis. The aim was to document the
impact of a cancer diagnosis on various outcomes in pa-
tients with type 2 diabetes, who took part in the DCGP
trial. In addition, we compared the effectiveness of struc-
tured personal diabetes care in patients with and without
cancer. Outcomes were all-cause mortality, diabetes-
related mortality, as well as cardiovascular and micro-
vascular complications.
Methods
A description of the study design has also been reported
earlier [16–18]. The DCGP study was a cluster-randomized,
open, controlled trial of the effect of intensified diabetes
management (ClinicalTrials.gov NCT01074762), and the
study adheres to CONSORT guidelines. A total number of
474 GPs volunteered to participate. Practices were randomly
allocated to provide either routine care or structured per-
sonal care to their patients, who were newly diagnosed with
type 2 diabetes.
Patients
The GPs included all of their patients who were 40 years
or older and diagnosed with diabetes during the inclu-
sion period. At a major laboratory, the diabetes diagnosis
was confirmed by a single fasting whole blood/plasma
glucose concentration (≥7.0/8.0 mmol/l). The protocol-
based exclusion criteria were: unwillingness to partici-
pate, severe psychiatric disease or life-threatening som-
atic disease (Additional file 1: Figure S1). As previously
reported, the randomization was balanced [16, 17]. In
total 1369 (99.1%) of 1381 patients in the final study
population were of Western European descent. Approxi-
mately 97.5% of the patients were classified as type 2
diabetes patients, which was based on the onset of insu-
lin treatment. The Frederiksberg and Copenhagen Re-
search Ethics Committee approved the study.
Intervention
The follow-up of patients in the intervention group con-
sisted of examinations every three months and annual
screening for diabetes complications. These examina-
tions were facilitated by a questionnaire forwarded to
the GP one month before the next expected consult-
ation. The GP together with the patient was asked to de-
fine optimal goals for controlling important risk factors
within three categories: ‘good,’ ‘acceptable,’ and ‘poor’
control. The emphasis was on glycemic control. At each
quarterly consultation, GPs should compare the patient’s
achievements with the goal and consider changing either
goal or treatment accordingly. In overweight patients,
the GP was prompted to agree with the patient on a
small, realistic weight reduction, and this agreement
should be recorded and followed up. However, partici-
pants were not required to target a particular body
weight [16].
Through folders and leaflets for both physicians and
patients, annual descriptive feedback reports on individ-
ual patients as well as six annual half-day seminars, GPs
were introduced to possible solutions to therapeutic
problems in the intervention group.
Generally, the importance of diet was stressed, and if
possible, the GPs were recommended to postpone the
start of glucose-lowering drugs until at least three months
after diabetes diagnosis, to observe the effect of any weight
loss. Further, the GPs were also prompted to recommend
increased physical exercise and simple dietary rules [16,
17]. In cases of persistent hyperglycemia, metformin was
recommended for patients who were overweight by clin-
ical judgment. Glipizide or glibenclamide was suggested
for patients of normal weight, and tolbutamide was rec-
ommended in patients older than 70 years. If the goal for
blood glucose was not achieved and before starting insu-
lin, a combination of metformin and a sulfonylurea was
suggested as the last step. The preferred treatments for
patients with hypertension were ACE-inhibitors or β-
blockers; however, for patients with heart failure furosem-
ide was preferred, and for patients older than 70 years
thiazides were recommended. In cases of diet-resistant
dyslipidemia, lipid-lowering drugs were recommended. To
individualize the treatment, the GPs were allowed to devi-
ate from the recommendations.
During the intervention phase, the GPs in the routine
care group were free to choose any treatment and also
to revise it [16]. The intervention was terminated on 26
September 1995, and the six-year examination was
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initiated. The study coordinators did not contact routine
care practices during the intervention period after re-
cruitment was completed and no attempt was made to
maintain patients in randomized groups or to influence
their therapy in the post-intervention period.
Clinical and registry-based follow-up
A description of all variables and definitions has previ-
ously been published [16–19]. After median (IQR) 5.57
(4.96–6.16) years in the structured personal care group
and after 5.85 (5.30–6.45) years in the routine care
group, a clinical follow-up examination was completed
for 970 (93.4%) of 1039 surviving patients (Additional
file 1: Figure S1).
Using the unique identification number assigned to all
Danish residents in the Danish Civil Registration System,
emigration and vital status of all patients were ascertained.
This enabled unambiguous linkage between the study
population and the Danish national registries [20]. On 31
December 2008, all surviving patients were censored. The
Danish Register of Causes of Death supplied information
about possible and underlying contributory causes of
death [21]. In four patients, the cause of death was not re-
corded. Information on cancer diagnoses was obtained
from The Danish Cancer Registry [22], however non-
melanoma skin cancer and some ill-defined cancers were
not included in our cancer diagnosis (Additional file 1:
Table S1). The Danish National Patient Register gave
information on contacts with hospitals in Denmark, e.g.,
surgical procedures performed and discharge diagnoses
[23]. These registries provided information on the
predefined outcomes: all-cause mortality, diabetes-
related deaths, any diabetes-related endpoint, stroke,
myocardial infarction, microvascular disease, and periph-
eral vascular disease [16] (Additional file 1: Table S2).
Statistical analysis
A description of the study design has also been re-
ported earlier [16–18]. The incidence rates of the out-
comes defined above were compared between
structured care and routine care with hazard ratios
(HRs) from Cox regression models on time from
diagnosis to the first occurrence of the outcome;
death and end of follow-up were censoring events. In
these models, the accrual of a cancer diagnosis was
modeled as a time-varying covariate. These compari-
sons were performed for patients with and without a
cancer diagnosis separately to be able to assess
whether there is a differential effect. Concurrently, in
an auxiliary Cox regression analysis, the incidence
rates for cancer were compared between structured
care and routine care; these incidences are visualized
in Kaplan-Meier curves. If a patient had an occur-
rence of an outcome before the diabetes diagnosis,
this patient was excluded from the analyses about
that outcome. In all assessments, we used a robust
sandwich estimator to determine 95% CIs and P
values to adjust for the clustering of patients within
practices [24]. We further adjusted the comparisons
for the following variables, assessed at diagnosis: sex,
age, body mass index, hypertension, diagnostic fasting
plasma glucose, total cholesterol, living alone, basic
school education, sedentary physical activity, and
current smoking. Incidence rates were calculated as
the number of patients experiencing the correspond-
ing outcome divided by the total person-time at risk.
Patients with missing values in one or more variables
were omitted from analyses where these variables
were included.
Comparisons between structured care and routine care
were done according to the intention-to-treat principle.
Analyses were done using SAS (version 9.4). The level of
statistical significance was 5%.
Results
At diabetes diagnosis, 48 of 1381 patients had a cancer
diagnosis and the distribution of several characteristics,
e.g., gender, fasting triglycerides, and current smoking
seem to be unbalanced in relation to randomization arm
in this small group (Tables 1 and 2). At the end of the
intervention period, on average six years after the diag-
nosis of type 2 diabetes, 67 of 970 surviving and re-
examined patients had cancer. At this point, levels of
many of the clinical characteristics in these 67 patients
(e.g., HbA1c and blood pressures) was similar to those of
the whole study population [16, 17] (Tables 1 and 2).
This indicates that the effect of the intervention on
intermediate outcomes was similar for patients with and
without concomitant cancer. During the entire follow-up
period of 19 years, including 13 years of post-
intervention follow up, 243 patients were diagnosed with
cancer (Additional file 1: Table S1). The occurrence of
cancer diagnoses in the two arms of the trial over the
study period is shown in Fig. 1. The rate of new cases of
cancer does not differ between the two arms (log-rank
test P = 0.28). Also, in a Cox regression model compar-
ing the cancer incidences in the two arms, adjusted for
the same variables as in Table 3, there is no evidence for
a difference: HR for structured personal care (95% CI) is
1.10 (0.84–1.43), P = 0.50.
Independent of the randomization group, the inci-
dence rate for each individual outcome was greater
among cancer patients than among non-cancer patients
during the 19 years of follow-up (Table 3). In
multivariable-adjusted analyses, the excess all-cause
mortality (HR 3.33) and diabetes-related mortality (HR
1.81) for cancer patients were confirmed. However,
among the five remaining predefined outcomes, only the
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Table 1 Characteristics of patients with cancer at diabetes diagnosis and after 6 years of intervention
Diabetes diagnosis (n = 48) After 6 years of intervention (n = 67)
n (structured care/
routine)
Structured
personal care
Routine
care
n (structured care/
routine)
Structured personal
care
Routine
care
Sociodemographic
Age (years) 32/16 70.3 (8.4) 70.8 (7.7) 37/23 74.9 (7.8) 72.9 (9.9)
Male gender 32/16 13 (40.6) 10 (62.5) 40/27 17 (42.5) 13 (48.2)
Live alonea 32/16 14 (43.8) 5 (31.3) 34/22 18 (52.9) 10 (45.5)
Basic School educationa 32/14 30 (93.8) 13 (92.9) 39/25 32 (82.1) 19 (76.0)
Clinical
Body mass index (kg/m2) 31/16 28.9 (4.4) 28.9 (3.9) 35/23 27.7 (5.0) 28.9 (4.7)
Hypertension 32/16 23 (71.9) 14 (87.5) 37/23 26 (70.3) 21 (91.3)
Systolic blood pressure (mmHg) 31/16 153.2 (25.5) 152.4
(16.0)
36/23 147.1 (20.7) 153.3
(15.3)
Diastolic blood pressure (mmHg) 31/16 83.7 (8.7) 85.8 (12.3) 36/23 78.2 (11.0) 84.1 (9.2)
Anti-diabetes treatment 37/23
Diet only – – 11 (29.7) 9 (39.1)
Oral anti-diabetes treatment – – 23 (62.2) 9 (39.1)
Insulin – – 3 (8.1) 5 (21.7)
Biochemical
Fasting plasma glucose# (mmol/l) 32/16 13.1 (4.9) 12.2 (3.2) 30/17 9.3 (3.8) 11.1 (7.0)
Haemoglobin A1c (%)b 23/15 9.8 (2.5) 9.8 (1.7) 35/21 8.4 (1.5) 9.0 (2.0)
Total cholesterol (mmol/l) 30/16 6.3 (1.7) 6.1 (1.2) 35/21 6.2 (1.2) 6.1 (1.3)
Fasting triglycerides (mmol/l) 30/16 3.14 (6.4) 1.76 (0.7) 33/18 2.21 (1.3) 2.24 (1.2)
Serum creatinine (μmol/l) 30/16 98.5 (29.5) 104.3
(25.4)
35/21 98.4 (36.2) 99.0
(31.7)
Urinary albumin 28/16 33/19
Normal 19 (67.9) 10 (62.5) 20 (60.6) 11 (57.9)
Microalbuminuria 9 (32.1) 6 (37.5) 11 (33.3) 8 (42.1)
Proteinuria 0 (0.0) 0 (0.0) 2 (6.1) 0 (0.0)
Behaviorala
Sedentary physical activity 32/16 9 (28.1) 4 (25.0) 34/22 15 (44.1) 8 (36.4)
Current smoking 32/16 9 (28.1) 1 (6.3) 34/22 11 (32.4) 4 (18.2)
Patient attitudesa
Self-rated health 32/16 34/22
Excellent 3 (9.4) 1 (6.3) 5 (14.7) 3 (13.6)
Good 9 (28.1) 4 (25.0) 7 (20.6) 12 (54.6)
Fair 15 (46.9) 10 (62.5) 19 (55.9) 6 (27.3)
Poor/very poor 5 (15.6) 1 (6.3) 3 (8.8) 1 (4.6)
Process of carea
No. of consultations last year – – 37/23 8.54 (4.7) 9.30 (6.2)
No. of diabetes-related consultations
last year
– – 37/23 4.19 (2.3) 4.26 (2.4)
Values are means (SD) or numbers (percentages of group). After 6 years of intervention, 27 of 48 patients with cancer at diagnosis were still alive and were re-
examined together with 40 patients who were diagnosed with cancer during the intervention period. aData from questionnaires to patients (behavioral) or their
general practitioners (process of care). bThe diagnostic value is limited to measurements from within 45 days of diabetes diagnosis. Reference range: 5.4–7.4%
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difference for MI (HR 1.76) and the aggregate outcome
of any diabetes-related outcome (HR 1.36) were statisti-
cally significant (Table 3).
Among patients without cancer, the intervention
reduced the risk of MI and any diabetes-related
outcome, a result that is consistent with the findings
in the main trial [16] (Table 4). We found no statisti-
cally significant difference in the effectiveness of the
intervention between patients with and without can-
cer. Furthermore, there was no clear trend as to
Table 2 Characteristics of diabetes patients without cancer at diabetes diagnosis and after 6 years of intervention
Diabetes diagnosis (n = 1333) After 6 years of intervention (n = 1002)
n (structured care/
routine)
Structured personal
care
Routine
care
n (structured care/
routine)
Structured personal
care
Routine
care
Sociodemographic
Age (years) 729/604 64.5 (11.6) 64.2 (11.4) 512/398 67.9 (11.0) 68.2 (10.9)
Male gender 729/604 391 (53.6) 319 (52.8) 556/446 17 (42.5) 13 (48.2)
Live alonea 711/590 222 (31.2) 193 (32.7) 472/382 163 (19.1) 132 (15.5)
Basic School educationa 691/574 544 (78.7) 446 (77.9) 531/427 412 (43.0) 329 (34.3)
Clinical
Body mass index (kg/m2) 722/603 29. (5.2) 29.5 (5.4) 502/387 29.0 (5.0) 28.8 (4.9)
Hypertension 729/604 545 (74.8) 444 (73.5) 512/398 371 (40.8) 291 (32.0)
Systolic blood pressure (mmHg) 724/603 149.2 (22.8) 147.3
(21.5)
510/392 146.8 (20.3) 151.4
(21.7)
Diastolic blood pressure (mmHg) 724/603 85.0 (10.9) 84.7 (10.8) 510/392 82.9 (9.4) 83.0 (10.7)
Anti-diabetes treatment 511/398
Diet only – – 148 (29.0) 122 (30.6)
Oral anti-diabetes treatment – – 303 (59.3) 222 (55.8)
Insulin – – 60 (11.7) 54 (13.6)
Biochemical
Fasting plasma glucose (mmol/l) 729/604 14.5 (5.4) 14.8 (5.9) 396/283 8.7 (3.4) 9.7 (3.7)
Hemoglobin A1c (%)b 601/497 10.3 (2.1) 10.3 (2.1) 504/393 8.7 (1.5) 9.2 (1.7)
Total cholesterol (mmol/l) 710/594 6.3 (1.5) 6.5 (1.7) 503/393 6.0 (1.4) 6.2 (1.2)
Fasting triglycerides (mmol/l) 706/594 2.6 (2.3) 2.9 (4.4) 470/338 2.2 (2.4) 2.3 (1.6)
Serum creatinine (μmol/l) 710/595 92.2 (19.1) 92.3 (21.9) 503/393 97.0 (51.8) 96.4 (29.5)
Urinary albumin 695/579 480/375
Normal 400 (57.6) 331 (57.2) 298 (34.9) 218 (25.5)
Microalbuminuria 259 (37.3) 219 (37.8) 162 (19.0) 135 (15.8)
Proteinuria 36 (5.2) 29 (5.0) 20 (2.3) 22 (2.57)
Behaviorala
Sedentary physical activity 709/588 201 (28.4) 158 (26.9) 466/379 128 (15.2) 120 (14.2)
Current smoking 710/588 255 (36.0) 207 (35.2) 470/377 151 (17.9) 112 (13.2)
Patient attitudesa
Self-rated health 712/590 472/381
Excellent 81 (11.4) 74 (12.5) 83 (9.73) 80 (9.4)
Good 243 (34.1) 192 (35.5) 206 (24.2) 141 (16.5)
Fair 321 (45.1) 259 (43.9) 158 (18.5) 144 (16.9)
Poor/very poor 67 (9.41) 65 (11.0) 25 (2.9) 16 (1.9)
Process of carea
No. of consultations last year – – 512/397 8.2 (6.5) 7.2 (5.5)
No. of diabetes-related consultations
last year
– – 512/397 5.2 (3.4) 4.4 (3.6)
Values are means (SD) or numbers (percentages of group)
aData from questionnaires to patients (behavioral) or their general practitioners (process of care)
bThe diagnostic value is limited to measurements from within 45 days of diabetes diagnosis. Reference range: 5.4–7.4%
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whether the intervention effect was larger or smaller
among cancer patients.
Discussion
To our knowledge, this is the first study to compare the
effect of a diabetes intervention in diabetes patients with
and without cancer. In this post hoc observational ana-
lysis with 19 years of follow up, we examined the effect-
iveness of structured personal diabetes care versus
routine diabetes care in diabetes patients with and
without cancer. Also, we evaluated the overall impact of
cancer in these patients with newly diagnosed type 2 dia-
betes. Our results demonstrate that compared to dia-
betes patients without cancer, patients with both
diabetes and cancer had significantly increased all-cause
and diabetes-related mortality as well as increased inci-
dence of any diabetes-related endpoint and MI. In the
original report from the DCGP trial, as well as in the
current study, the intervention was associated with a sig-
nificantly reduced risk of MI and any diabetes-related
endpoint in patients with type 2 diabetes [16]. However,
diabetes patients with cancer benefitted neither more
nor less from structured personal diabetes care com-
pared to diabetes patients without cancer.
It is well documented that cancer patients with dia-
betes have higher mortality than cancer patients without
diabetes [12, 25]. A Danish study found that for all can-
cers combined and diabetes duration of 2 years at cancer
diagnosis, patients treated with insulin experienced the
highest mortality rate ratios starting from 3.7 for men
and 4.4 for women one year after the cancer diagnosis
[12]. Our HR (3.3) for all-cause mortality is comparable
with these results. Similarly, other studies have shown
that patients with both cancer and diabetes have an in-
creased risk of death from MI, compared to cancer pa-
tients without diabetes [26].
The interaction between diabetes and cancer is complex
[27]. There is good evidence for biologic mechanisms
(e.g., hyperinsulinemia, hyperglycemia, inflammatory
pathways, oxidative stress, and changes in hormones) con-
tributing to the increased mortality risk when the diseases
occur simultaneously [28]. Further, certain shared risk fac-
tors may be involved, such as age, sex, body weight, diet,
physical activity, alcohol, and smoking, as these risk fac-
tors are likely to influence diabetes treatment as well as
diabetes-related outcomes. In addition, cardiovascular
complications of cancer chemotherapy and radiation are
common [29], as well as glucocorticoids used in cancer
treatment may also interfere with glucose metabolism and
cause diabetes, or worsen pre-existing diabetes. Further,
some antidiabetic drugs have been under scrutiny because
Fig. 1 The cumulative incidence of cancer during 20 years after
diabetes diagnosis according to randomization arm. Kaplan–Meier
curves. Solid line: structured personal care; dotted line: routine care
Table 3 Mortality and other outcomes during 19 years of follow up
Outcome Incidence rate (events per 1000 patient years, 95% CI) Hazard ratio
(95% CI)a for
cancer versus
no cancerb
P valuec
No cancer Cancer
All-cause mortality 48.3 (44.8–51.9) 226.7 (199.3–256.7) 3.33 (2.72–4.06) < 0.0001
Diabetes-related deaths 34.2 (31.3–37.3) 87.7 (71.1–107.2) 1.81 (1.41–2.32) <.0.0001
Any diabetes-related endpoint 64.3 (59.4–69.5) 418.7 (351.5–495.1) 1.36 (1.07–1.71) 0.011
Myocardial infarction 26.3 (23.6–29.2) 90.3 (71.2–113.1) 1.76 (1.29–2.39) 0.0003
Stroke 19.2 (16.9–21.7) 47.5 (34.3–64.3) 1.04 (0.68–1.57) 0.87
Peripheral vascular disease 4.16 (3.18–5.35) 7.54 (3.22–14.9) 0.92 (0.35–2.44) 0.86
Microvascular disease 10.4 (8.80–12.2) 33.4 (23.0–46.9) 1.44 (0.87–2.38) 0.16
aThe hazard ratio (HR) is calculated in a Cox proportional hazard regression model where the first cancer diagnosis is a time-varying covariate. The corresponding
95% CI and P values are determined using a sandwich estimator for the variance to account for clustering of patients within practices
bAdjusted for age, sex and clustering, as well as for the following variables at diagnosis: live alone, basic school education, body mass index, hypertension,
diagnostic fasting plasma glucose, total cholesterol, sedentary physical activity, and current smoking
cTests the effect of cancer versus no cancer within patients with type 2 diabetes mellitus
The influence of prevalent or incident cancer
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of their potential influences on cancer development in a
population already at risk [30]. Biologic mechanisms,
shared risk factors, as well as factors associated with treat-
ment, may, therefore, contribute to the increased mortal-
ity in patients with diabetes and cancer.
Other factors, such as changes in priorities in the man-
agement of comorbidities in cancer patients, could also
play a role in excess mortality. For instance, Sabatino et
al. [10] found that many providers may miss oppor-
tunities to counsel cancer survivors about important
behaviors regarding diet, exercise, and smoking, even
though these behaviors may influence the prognosis
of these patients. In like manner, patient priorities
might also change, as patients focus on new, compet-
ing demands, while pre-existing conditions attain a
lower priority [31]. E.g., studies have found that having
a comorbid disease or receiving chemotherapy is likely to
reduce patients’ prioritization and self-management of
diabetes [32, 33]. Further, management of chronic diseases
in patients with cancer is connected with lower testing
rates [11] and lower adherence to medication [34, 35]
resulting in difficulties meeting treatment goals for HbA1c,
LDL-cholesterol and blood pressure targets [36].
In contrast, Chiao et al. compared diabetes outcomes
one year before and after a colorectal cancer diagnosis in
American veterans with diabetes [37]. They found that
blood pressure and cholesterol levels remained un-
changed, whereas HbA1c levels showed a tendency to
improve. In addition, other studies [38–41] showed that
diabetes patients with cancer received diabetes care of
generally similar quality compared to diabetes patients
without cancer.
Table 4 Mortality and other outcomes for patients with and without cancer in patients receiving structured or routine care during
19 years of follow up
No. of patients with outcome
during 19 years of follow
up (n (%))
Incidence rate (events per 1000
patient years, 95% CI)
Hazard ratioa
(95% CI) for
structured care
versus routine
careb
P valuec Inter-ac-tion
P valued
Structured
personal care
Routine care Structured personal
care
Routine care
All-cause mortality
Cancer 147 (84.5) 101 (86.3) 220.1 (185.9–258.7) 237.0 (193.1–288.1) 0.97 (0.67–1.41) 0.89 0.65
No cancer 375 (63.9) 343 (68.2) 45.8 (41.3–50.7) 51.2 (45.9–56.9) 0.89 (0.76–1.03) 0.12
Diabetes-related deaths
Cancer 58 (33.5) 38 (32.5) 86.8 (65.9–112.3) 89.2 (63.1–122.5) 1.01 (0.63–1.63) 0.96 0.75
No cancer 269 (45.9) 240 (47.9) 32.8 (29.0–37.0) 35.8 (31.4–40.6) 0.93 (0.77–1.13) 0.46
Any diabetes-related endpoint
Cancer 79 (53.4) 58 (61.1) 339.8 (269.0–423.6) 612.5 (465.0–792.2) 0.75 (0.49–1.16) 0.19 0.81
No cancer 331 (70.6) 314 (75.3) 58.9 (52.8–65.7) 71.1 (63.5–79.4) 0.80 (0.68–0.93) 0.005
Myocardial infarction
Cancer 42 (25.2) 34 (31.2) 77.0 (55.5–104.1) 114.9 (79.5–160.7) 0.94 (0.53–1.69) 0.84 0.50
No cancer 177 (33.5) 176 (38.8) 23.7 (20.3–27.5) 29.5 (25.3–34.2) 0.76 (0.62–0.94) 0.011
Stroke
Cancer 23 (13.9) 19 (17.6) 43.4 (27.4–65.1) 53.9 (32.4–84.3) 0.65 (0.30–1.41) 0.27 0.38
No cancer 133 (23.7) 127 (26.3) 17.8 (14.9–21.1) 21.0 (17.5–25.0) 0.94 (0.74–1.11) 0.60
Peripheral vascular disease
Cancer 4 (2.3) 4 (3.5) 6.1 (1.6–15.8) 9.8 (2.6–25.4) 0.85 (0.49–1.48) 0.99 0.88
No cancer 31 (5.3) 30 (6.0) 3.8 (2.6–5.5) 4.6 (3.1–6.5) 0.99 (0.16–6.13) 0.57
Microvascular disease
Cancer 20 (11.6) 13 (11.1) 33.4 (20.4–51.7) 33.3 (17.7–56.2) 1.35 (0.51–3.57) 0.37 0.39
No cancer 78 (13.3) 70 (13.9) 9.9 (7.8–12.4) 11.0 (8.6–13.9) 0.85 (0.60–1.21) 0.55
aThe hazard ratio (HR) is calculated in a Cox proportional hazard regression model where the first cancer diagnosis is a time-varying covariate. The corresponding
95% CI and P values are determined using a sandwich estimator for the variance to account for clustering of patients within practices
bAdjusted for age, sex and clustering, as well as for the following variables at diagnosis: live alone, basic school education, body mass index, hypertension,
diagnostic fasting plasma glucose, total cholesterol, sedentary physical activity, and current smoking
cTests the effect of randomization within patient groups with and without cancer. dTests whether the effect of randomization is different between patient groups
with and without cancer
The effectiveness of the intervention
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In the present study, the number of consultations
among cancer patients in the two study arms showed no
significant difference after six years of intervention.
Strengths and limitations
The results from this post hoc analysis of a randomized
controlled trial should be interpreted as observational,
as the presence of cancer was not accounted for in the
randomization procedure. In the period following a dia-
betes diagnosis, the enhanced medical examination
could lead to increased detection of cancer, which has
been reported in some studies [42] and rejected in an-
other study [43]. However, in the present study, the
intervention did not influence the detection of cancer
(Fig. 1), as the rate of new cases of cancer did not differ
between the two arms.
The distribution of types of cancers resulted in rela-
tively small numbers of patients in different sub-classes
of cancer (Additional file 1: Table S1), which prevented
us from making subgroup analyses according to cancer
type and stage. An observational study did not find any
effect of tumor stage and site on diabetes quality indica-
tors among cancer patients [38]. Nevertheless, it seems
reasonable to assume that aggressive lung cancer or pan-
creatic cancer has a larger impact on the course of dia-
betes than limited skin cancers, which are not included
in this study.
The group of patients who had cancer recorded be-
fore the diabetes diagnosis included only patients who
had survived this cancer, and it did not include pa-
tients with terminal cancers as this was an explicit
exclusion criterion. The group of patients who got a
cancer diagnosis after the diabetes diagnosis did in-
clude more aggressive type of cancers. It is, therefore,
a limitation of the present study that the effect of
cancer was modeled without taking the timing of the
cancer diagnosis into account. People who did not
survive probably had more severe conditions and
could have been treated less intensively as regards
their diabetes and diabetic complications.
The cancer diagnoses were identified in the Danish
Cancer Registry, which has been documented to have
high completeness and accuracy [22, 44] (Additional
file 1: Table S1).
Conclusions
In this post hoc analysis of the DCGP trial, diabetes
patients with cancer had significantly increased mor-
tality, an increased incidence of myocardial infarction,
as well as an increased incidence of the aggregate
endpoint any diabetes-related outcome, compared to
patients without cancer. The intervention reduced the
risk of MI and any diabetes-related outcome in pa-
tients without cancer, and there were no statistically
significant differences in the effectiveness of the inter-
vention between patients with and without cancer.
The observed high risk of cardiovascular disease
among patients with both diabetes and cancer sug-
gests that this late complication should receive extra
attention in this group of high-risk patients.
Additional file
Additional file 1: Table S1. Categorization of all patients from the
Diabetes Care in General Practice (DCGP) study with ICD-10 diagnoses in
the Danish Cancer Register (DCR). Table S2. Definition of clinical out-
comes in the 19-year registry-based monitoring of the Diabetes Care in
General Practice (DCGP) study. Figure S1. Patient flow through study.
(DOCX 110 kb)
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